The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
Abstract
Purpose: The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly in wild-type KRAS tumors. Cetuximab may also exert antitumor effects through antibody-dependent cell-mediated cytotoxicity (ADCC) in which antibody Fc portion interacts with Fc receptors (FcγRs) expressed by immune cells. ADCC is influenced by FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms that are clinically relevant in follicular lymphoma and metastatic breast cancer treated with rituximab and trastuzumab, respectively. We investigated the association of FcγR polymorphisms and KRAS mutation with the outcome of irinotecan-refractory mCRC patients treated with cetuximab plus irinotecan. Patients and Methods: Tumor and normal tissues from 69 patients were screened for KRAS mutations using a sensitive multiplex assay and genotyped for FcγRIIa and FcγRIIIa polymorphisms by direct sequencing and multiplex allele-specific polymerase chain reaction, respectively. The results were correlated with response and progression-free survival (PFS). Results: KRAS mutations were associated with lower response rate (4% v 27% in nonmutated patients; P = .021) and shorter PFS (3.0 v 5.3 months; P = .021). Patients with FcγRIIa-131H/H and/or FcγIIIa-158V/V genotypes had longer PFS than 131R and 158F carriers (5.5 v 3.0 months; P = .005). The difference remained significant for mutated-KRAS patients. By multivariate analysis, KRAS mutation and FcγR combined status were independent risk factors for PFS. Conclusion: Combined FcγRIIa/FcγRIIIa polymorphisms are prognostic factors for disease progression in mCRC patients treated with cetuximab plus irinotecan. As these polymorphisms are also clinically relevant in mutated-KRAS mCRC, an important role of ADCC in cetuximab efficacy is presumed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, it is believed that microenvironment remodelling can reduce the cytotoxicity of anti-EGFR mAbs by impairing antibody-dependent cellular cytotoxicity (ADCC) and secreting growth factors [19, 20].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [20]
In the citing paper
“Antibody-dependent cellular cytotoxicity (ADCC) mediated through Fc receptors (FcγRs) on immune cells is one of the proposed antitumour mechanisms of anti-EGFR mAbs [20].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [20]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Self-citationCartron, G., Dacheux, L., Salles, G. A., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,954
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Lièvre, A., Bachet, J., Boige, V., Cayre, A., Corre, D. L., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,485
Self-citationWeng, W., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,324
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Sobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausová, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 955
Moroni, M., Veronese, S., Benvenuti, S., Marrapese, G., Sartore-Bianchi, A., Di Nicolantonio, F., Gambacorta, M., Siena, S., & Bardelli, A. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70102-9 · Cited by 941
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Koene, H. R., Kleijer, M., Algra, J., Roos, D., Borne, A. E. G. K. V. D., & de Haas, M. (1997) · Blood · doi:10.1182/blood.v90.3.1109 · Cited by 796
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Self-citationArnould, L., Gelly-Marty, M., Penault-Llorca, F. M., Benoît, L., Bonnetain, F., Migeon, C., Cabaret, V., Fermeaux, V., Bertheau, P., Garnier, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602930 · Cited by 567
Self-citationPTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
Frattini, M., Saletti, P., Romagnani, E., Martin, V, Molinari, F., Ghisletta, M., Camponovo, A., Etienne, L. L., Cavalli, F., & Mazzucchelli, L. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604009 · Cited by 540
Lenz, H., Cutsem, E. V., Khambata‐Ford, S., Mayer, R. J., Gold, P. J., Stella, P. J., Mirtsching, B. C., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Zhang, W., Gordon, M. A., Schultheis, A. M., Yang, D., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 487
Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines
Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1726 · Cited by 435
Parren, P. W. H. I., Warmerdam, P. A. M., Boeije, L. C. M., Arts, J. A. J., WESTERDAAL, N. A. C., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346
Kyogoku, C., Dijstelbloem, H. M., Tsuchiya, N., Hatta, Y., Kato, H., Yamaguchi, A., Fukazawa, T., Jansen, M., Hashimoto, H., van de Winkel, J. G. J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10257 · Cited by 333
Cutsem, E. V., Nowacki, M. P., Láng, I., Cascinu, S., Shchepotin, I. B., Maurel, J., Rougier, P. R., Cunningham, D., Nippgen, J., & Köhne, C.-H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4000 · Cited by 313
FcγR polymorphisms: Implications for function, disease susceptibility and immunotherapy
van Sorge, N. M., van der Pol, W.-L., & van de Winkel, J. G. J. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00037.x · Cited by 293
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Farag, S. S., Flinn, I. W., Modali, R., Lehman, T. A., Young, D. C., & Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2003-07-2548 · Cited by 208
Personeni, N., Fieuws, S., Piessevaux, H. H., Hertogh, G. D., Schutter, J. D., Biesmans, B., Roock, W. D., Capoen, A., Dêbiec‐Rychter, M., Laethem, J. V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 176
Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fujii, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22370 · Cited by 176
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 133
Structural motifs involved in human IgG antibody effector functions
Greenwood, J., Clark, M., & Waldmann, H. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230518 · Cited by 126
Scartozzi, M., Bearzi, I., Pierantoni, C., Mandolesi, A., Loupakis, F., Zaniboni, A., Catalano, V., Quadri, A., Zorzi, F., Berardi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5022 · Cited by 124
Monoclonal antibody mechanisms of action in cancer
Weiner, G. J. (2007) · Immunologic Research · doi:10.1007/s12026-007-0073-4 · Cited by 122
Lin, T. S., Flinn, I. W., Modali, R., Lehman, T. A., Webb, J. L., Waymer, S., Moran, M. E., Lucas, M. S., Farag, S. S., & Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-02-0651 · Cited by 80
Dall’Ozzo, S., Andres, C. R., BARDOS, P., Watier, H., & Thibault, G. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00123-6 · Cited by 60
2008 Gastrointestinal Cancers Symposium
Fricker, J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70054-8 · Cited by 46
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer
Spano, J., Milano, G. A., Vignot, S., & Khayat, D. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.11.005 · Cited by 44
Personeni, N., Hendlisz, A., Gallez, J., Galdón, M. G., Larsimont, D., VANLAETHEM, J., NAGY, N., Barette, M., Paesmans, M., & Cardoso, F. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.04.029 · Cited by 30
Raynaud, P., Caulet-Maugendre, S., Foussard, C., Salles, G., Moreau, A., Rossi, J. F., Patey, M., Béné, M. C., Béné, M. C., Damotte, D., et al. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.05.026 · Cited by 26
Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy
Sako, T., Burioka, N., Yasuda, K., Tomita, K., Miyata, M., Kurai, J., Chikumi, H., Watanabe, M., Suyama, H., Fukuoka, Y., et al. (2004) · Acta Oncologica · doi:10.1080/02841860310016226 · Cited by 23
Kang, X., Patel, D., Ng, S. K., Melchior, M., Ludwig, D. L., & J, D. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3041 · Cited by 22
Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma
Pennell, N., Bhanji, T., Zhang, L., Seth, A. K., Sawka, C. A., & Berinstein, N. L. (2008) · Haematologica · doi:10.3324/haematol.12638 · Cited by 11
Flagged first, then by citations
Research works printed but not linked: 2
- Van Cutsem E, 2007, J Clin Oncol, 25, 164s
- Kang X, 2007, J Clin Oncol, 25, 128s
Cited by
Sorted by citations
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3236 · Cited by 2,244
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationMacrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,339
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C. A., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 983
Metadata
- Authors
- Bibeau, F., Lopez-Crapez, E., Di Fiore, F., Thezenas, S., Ychou, M., Blanchard, F., Lamy, A., Penault-Llorca, F., Frébourg, T., Michel, P., Sabourin, J.-C., & Boissière-Michot, F.
- Affiliations
- Inserm (FR)
- From the Departments of Pathology, Biology, Biostatistics, and Oncology, Centre Régional de Lutte Contre le Cancer Val d'Aurelle-Paul Lamarque, Montpellier; Digestive Oncology Unit, Department of Gastroenterology, Rouen University Hospital; Inserm U614, Faculty of Medicine; Department of Pathology, Rouen University Hospital; and the Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-03-01
- Volume
- 27
- Issue
- 7
- Pages
- 1122-1129
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122618533
- Cited by
- 521
- References
- 44
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 12 · 2023: 19 · 2022: 16 · 2021: 17 · 2020: 24 · 2019: 16 · 2018: 26 · 2017: 24 · 2016: 32 · 2015: 40 · 2014: 41 · 2013: 46 · 2012: 53
- FWCI
- 31.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- FcγRIIIa, Fc receptor polymorphism, KRAS mutation, cetuximab, irinotecan, metastatic colorectal cancer, antibody-dependent cellular cytotoxicity, progression-free survival, prognostic factors, irinotecan-refractory disease, epidermal growth factor receptor
- MeSH terms
- Cetuximab, Irinotecan, Antibodies, Monoclonal, Antibody-Dependent Cell Cytotoxicity, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Mutation, Polymorphism, Genetic, Proto-Oncogene Proteins, Retrospective Studies, Colorectal Neoplasms, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Proto-Oncogene Proteins p21(ras), Receptors, IgG, Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
